> Research Use Only Disclaimer: GHK-Cu (copper tripeptide-1) is a research compound. All dosage information in this article is sourced from peer-reviewed literature and is provided for research and educational purposes only. It is not intended for human use, diagnosis, or treatment. Always follow your institution's protocols and applicable regulations.
---
What Is GHK-Cu?
GHK-Cu (glycine-histidine-lysine copper complex) is a naturally occurring tripeptide that forms a stable complex with copper(II) ions. First isolated from human plasma in 1973 by Loren Pickart, it is found in blood, saliva, and urine, and plays a key role in tissue remodeling, wound healing, and cellular signaling.
GHK-Cu is one of the most studied peptides in the anti-aging and regenerative research space. Its activities include:
- •Collagen and elastin synthesis stimulation — upregulates genes for type I and III collagen, fibronectin, and decorin
- •Anti-inflammatory modulation — downregulates TNF-α, IL-6, and NF-κB pathways
- •Antioxidant activity — scavenges free radicals; upregulates SOD and catalase
- •Wound healing acceleration — stimulates keratinocyte migration and angiogenesis
- •Gene expression remodeling — preclinical data suggests modulation of 31% of genes associated with aging (Pickart & Margolina, 2018)
Unlike many growth factors, GHK-Cu is small enough (MW ~340 Da) to penetrate the stratum corneum without assistance, though penetration enhancers significantly increase delivery depth.
---
Forms Available for Research
GHK-Cu is available in two primary forms for research settings:
| Form | Description | Typical Concentration |
|---|---|---|
| Topical solution / serum | Water-based solution with GHK-Cu at defined % w/v | 0.1% – 3% |
| Lyophilized powder | Freeze-dried peptide for reconstitution (injectable research) | 50 mg, 100 mg, 200 mg vials |
| Cosmetic serum | Pre-formulated consumer products | 0.01% – 0.5% (lower ranges) |
For subcutaneous research applications, the lyophilized powder form is reconstituted with bacteriostatic water (BW) following standard aseptic technique.
---
Topical Application Protocols
Concentration Ranges from the Literature
The topical application of GHK-Cu has been studied across a range of concentrations. The following table summarizes findings from published research:
| Concentration | Primary Application | Key Literature Finding |
|---|---|---|
| 0.1% | Baseline skin barrier support | Detectable increase in collagen mRNA expression (Finkley et al., 2007) |
| 0.3% – 0.5% | Anti-aging / photoaged skin | Statistically significant increase in collagen density vs placebo (Leyden et al., 2009) |
| 1% | Wound healing research | Accelerated re-epithelialization in murine models; increased keratinocyte migration |
| 2% – 3% | Intensive wound / scar research | Maximal stimulation of MMP-2/TIMP-2 ratio; increased tensile strength in excisional models |
Recommended topical research protocol (0.3%–1%):
- •Apply 2–4 drops (approx. 0.3–0.5 mL) to the target tissue area
- •Gently press into skin; do not rub aggressively
- •Frequency: once or twice daily in most study designs
- •No occlusion required at standard concentrations; occlusion may increase penetration at 0.1%–0.5%
- •Allow 5–10 minutes to absorb before other topical agents
pH Considerations
GHK-Cu has optimal stability and bioactivity at pH 6.5–7.5. Solutions outside this range (especially below pH 5) can cause copper disassociation and reduced efficacy. When compounding for research, verify pH of the final formulation.
Frequency and Duration in Literature
Most peer-reviewed topical studies run for 8–12 weeks with twice-daily application to detect statistically significant changes in collagen or wound markers. Shorter durations (4 weeks) show measurable gene expression changes but less histological remodeling.
---
Skin Penetration Enhancement Strategies
Microneedling (Dermal Stamping)
Microneedling creates transient microchannels in the epidermis, dramatically increasing GHK-Cu delivery to the dermis. Research protocols typically apply GHK-Cu immediately after microneedling (within 5–10 minutes while channels are open):
- •Needle depth: 0.25 mm – 1.5 mm depending on target tissue
- •GHK-Cu concentration: 1%–3% for post-needling application in research contexts
- •Frequency: Every 3–6 weeks in intervention studies; more frequent intervals may impair tissue regeneration
Microneedling + GHK-Cu studies report synergistic increases in collagen type I, VEGF, and TGF-β1 compared to either treatment alone (Fabbrocini et al., 2014).
DMSO (Dimethyl Sulfoxide) as Carrier
DMSO is an established penetration enhancer in research settings. At 10%–20% DMSO concentrations, transdermal GHK-Cu delivery increases significantly, reaching deeper dermal layers. However:
- •DMSO carries other substances transdermally — solution purity is critical
- •Concentrations above 30% DMSO can cause local irritation
- •DMSO use in research requires adherence to institutional safety protocols
Liposomal Encapsulation
Liposomal GHK-Cu formulations (phosphatidylcholine encapsulation) have shown improved dermal retention and sustained release in in vitro models. This is an active area of formulation research.
---
Subcutaneous Research Dosing
Overview
Subcutaneous (SC) administration of reconstituted GHK-Cu is used in preclinical and translational research to study systemic effects on inflammation, organ repair, and gene expression. Published subcutaneous dosing data comes primarily from murine and rodent models, with extrapolation to human research use following standard scaling methodologies.
Reconstitution Protocol
For lyophilized GHK-Cu powder:
| Powder Amount | Bacteriostatic Water (BW) | Resulting Concentration | Notes |
|---|---|---|---|
| 50 mg | 5 mL BW | 10 mg/mL (1%) | Standard SC research concentration |
| 50 mg | 2.5 mL BW | 20 mg/mL (2%) | Higher concentration for smaller volumes |
| 100 mg | 10 mL BW | 10 mg/mL (1%) | Larger batch |
| 200 mg | 20 mL BW | 10 mg/mL (1%) | Bulk research vial |
Reconstitution steps:
1. Allow lyophilized vial to equilibrate to room temperature (15–20 min)
2. Clean vial septum with 70% isopropyl alcohol
3. Draw required volume of bacteriostatic water with an 18–20G needle
4. Inject BW slowly down the inside wall of the vial (not directly onto powder)
5. Gently swirl — do not shake or vortex
6. Allow 5 minutes for complete dissolution
7. Solution should be clear and colorless (slight blue tint is normal due to copper chelation)
> Use the Peptides.SO reconstitution calculator for exact volume calculations.
Subcutaneous Dosing Ranges from Literature
| Research Model | Dose Range | Frequency | Reference |
|---|---|---|---|
| Murine wound healing | 1–10 mg/kg SC | Daily or 3x/week | Pickart et al. (1973, 1983) |
| Rodent anti-inflammatory | 0.5–5 mg/kg SC | Daily | Multiple FASEB publications |
| In vitro / cell studies | 0.01–10 μM | Continuous media | Numerous (Matalka et al., 2023) |
For human research extrapolation (not for human administration), scaling from murine 5 mg/kg using FDA body surface area conversion (Km factor 37 for humans vs 3 for mice) gives an approximate human-equivalent dose of ~0.4 mg/kg. This is a computational reference only.
---
GHK-Cu vs. Retinol and Other Anti-Aging Compounds
A common question in research is how GHK-Cu compares mechanistically to established anti-aging compounds:
| Compound | Mechanism | Onset of Effect | Irritation Potential | RUO Status |
|---|---|---|---|---|
| GHK-Cu (1%) | Copper-mediated collagen gene expression, TGF-β1 upregulation | 8–12 weeks | Very low | Research compound |
| Retinol (0.1%) | RAR/RXR nuclear receptor activation, collagen transcription | 12–16 weeks | Low–moderate | OTC ingredient |
| Retinoic acid (0.025%–0.1%) | Direct RAR activation | 8–12 weeks | Moderate–high | Rx only |
| Vitamin C (10–20%) | Hydroxylation cofactor, antioxidant | 12 weeks | Low–moderate | OTC ingredient |
| Peptide combinations | Multiple pathways | Variable | Low | Research dependent |
Key differences from the literature:
- •GHK-Cu operates via epigenetic and copper-dependent signaling, not nuclear receptor activation
- •GHK-Cu has documented anti-inflammatory activity while retinoids often cause initial inflammation
- •Studies comparing direct application show GHK-Cu may be superior for wound healing endpoints while retinoids have stronger evidence for photo-damage reversal
- •Combination approaches (GHK-Cu + vitamin C) show additive effects on collagen mRNA in fibroblast culture models
---
Safety and Copper Overload Considerations
GHK-Cu has a strong safety profile in the literature at standard research concentrations. Key considerations:
Topical Safety
- •No documented cases of copper toxicity from topical cosmetic use at concentrations up to 3%
- •GHK-Cu delivers copper in chelated form; bioavailable copper from topical application is a fraction of dietary copper intake
- •Mild transient redness possible in sensitive skin; resolves within hours
Systemic Copper Considerations (Subcutaneous Research)
- •Recommended daily copper intake (RDA): approximately 0.9 mg/day for adults
- •At research subcutaneous doses, total copper delivered per administration should be modeled
- •50 mg GHK-Cu contains approximately 9.4 mg elemental copper (based on MW); however, biological availability is modulated by chelation kinetics
- •Research involving repeated high-dose systemic administration should monitor copper status markers: serum ceruloplasmin, serum copper, and 24-hour urine copper
Known Contraindications (from literature)
- •Wilson's disease (copper metabolism disorder) — copper compounds contraindicated
- •High-copper status at baseline — monitor accordingly
- •Concurrent use with high-dose zinc supplementation may interfere (copper-zinc antagonism)
---
Storage and Stability
| Form | Recommended Storage | Shelf Life |
|---|---|---|
| Lyophilized powder (sealed) | –20°C to –80°C preferred; –4°C acceptable short-term | 24+ months at –20°C |
| Reconstituted solution | 2°C–8°C (refrigerated); away from light | 28–30 days with bacteriostatic water |
| Topical serum (unopened) | Room temperature, dark storage | Per manufacturer (typically 12–24 months) |
| Topical serum (opened) | Refrigerated recommended | 3–6 months |
Key storage notes:
- •Never freeze reconstituted GHK-Cu solution (freeze-thaw cycles degrade the peptide)
- •Light exposure accelerates oxidation of the copper complex; use amber vials
- •Do not expose to temperatures above 37°C for extended periods
---
Key Research Takeaways
1. Topical dosing: 0.3%–1% GHK-Cu twice daily represents the most researched concentration range for dermal collagen outcomes
2. Microneedling synergy is among the strongest documented combination strategies — apply GHK-Cu within 5–10 minutes of needling
3. Subcutaneous research should follow institutional protocols; reconstitute with bacteriostatic water at 10 mg/mL for standard concentration
4. Safety profile is favorable at standard research concentrations; systemic dosing warrants copper status monitoring
5. Storage is critical — lyophilized powder should be kept frozen; reconstituted solution must be refrigerated and used within 30 days
---
Internal Resources
- •GHK-Cu Research Guide: Anti-Aging Science & Applications (2026) — broader research overview including mechanisms and supplier comparison
- •Best Peptides for Skin and Hair: Copper Peptides (2026) — comparative guide across cosmetic peptides
- •Reconstitution Calculator — calculate exact volumes for your GHK-Cu vial size
- •Compare Copper Peptide Suppliers — side-by-side quality, pricing, and testing transparency
---
> For Research Use Only. All dosage information presented is derived from published scientific literature and is intended exclusively for research purposes. GHK-Cu is not approved by the FDA for human therapeutic use. This content does not constitute medical advice. Consult qualified research professionals and follow all applicable regulatory guidelines.